Michael O'Neill

Michael O'Neill is the Director of R&D at Inflection Biosciences, an oncology drug development company that licenses early-stage assets from global centres of excellence in oncology research and develops them to significant preclinical milestones. With years of experience in scientific strategy and operations, Michael leads the company's research and development initiatives.

In June 2013, Inflection Biosciences announced that it licensed a series of PIM kinase inhibitors from the Spanish National Oncology Research Organisation (CNIO) in Madrid. These molecules offer a unique combination of inhibition of PIM and PI3K as treatments for haematological malignancies and difficult-to-treat cancers such as oesophageal, gastric, and NSCLC. Currently, these compounds are undergoing a Candidate Selection process.

With Michael's expertise in scientific strategy and operations, Inflection Biosciences is well-poised to bring innovative and effective oncology treatments to market.